Sail Biomedicines
Sail combines eRNA with targeted nanoparticles for in vivo CAR-T in immune-mediated diseases. Its July 2026 Johnson & Johnson collaboration includes an option to acquire Sail, not a completed acquisition. A named clinical CAR-T candidate is not established by this announcement.
Corporate information
- Company entity
- Sail Biomedicines
- Headquarters / principal office
- Cambridge, Massachusetts, United States ↗
- Founded
- 2023 ↗
- Ownership / capital status
- PrivateJ&J strategic equity investment (announced) ↗
- Official corporate reference
- https://www.sail.bio/news/sail-biomedicines-announces-strategic-collaboration-to-develop-new-class-of-medicines-for-in-vivo-car-t/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-07-29 · J&J strategic equity investment (announced) · US$465 million equity investment; separate from US$785 million collaboration arrangements ↗
Disclosed equity event found in this review; not a claim that no later undisclosed event exists.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Sail combines eRNA with targeted nanoparticles for in vivo CAR-T in immune-mediated diseases. Its July 2026 Johnson & Johnson collaboration includes an option to acquire Sail, not a completed acquisition. A named clinical CAR-T candidate is not established by this announcement.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.